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CompetitionIt has been shown that siRNAs can compete with each other or with endogenous miRNAs for RISC components.
This competition may complicate the interpretations of phenotypes observed through siRNA-mediated knock-
down of genes, especially those genes implicated in the RISC pathway. In this study, we re-examined the function
of RNA helicase A (RHA), which has been previously proposed to function in RISC loading based on siRNA-
mediated knockdown studies. Here we show that reduced RISC activity or loading of siRNAs was observed
only in cells depleted of RHA using siRNA, but not using RNaseH-dependent antisense oligonucleotides (ASOs),
suggesting that the impaired RISC function stems from the competition between pre-existing and newly
transfected siRNAs, but not from reduction of the RHA protein. This view is further supported by the ﬁndings
that cells depleted of a control protein, NCL1, using siRNA, but not ASO, exhibited similar defects on the loading
and activity of a subsequently transfected siRNA. Transfection of RHA or NCL1 siRNAs, but not ASOs, reduced the
levels of endogenousmiRNAs, suggesting a competitionmechanism. As a positive control, we showed that reduc-
tion ofMOV10 by either siRNA orASO decreased siRNA activity, conﬁrming its role in RISC function. Together, our
results indicate that RHA is not required for RISC activity or loading, and suggest that proper controls are required
when using siRNAs to functionalize genes to avoid competition effects.
© 2013 The Authors. Published by Elsevier B.V. All rights reserved.1. Introduction
RNA interference (RNAi) is a commonly used technique to character-
ize genes by speciﬁcally degrading the target mRNAs [1]. This process is
mediated by small interfering RNAs (siRNAs), 21–24 nts double stranded
RNAs (dsRNAs). The double stranded siRNAs are loaded into the RNA in-
duced silencing complex (RISC) containing Ago2. The passenger strand
siRNA is then released, whereas the guide strand siRNA remains associat-
edwith Ago2 and directs the RISC to cleave the complementary substrate
mRNAs (e.g., [2–4]). In addition to siRNAs, endogenously expressed
miRNAs also utilize overlapping RISC components to function mainly in
down-regulating gene expression either by inhibiting translation or by
modulating mRNA stability [3,4].
Since siRNAs and miRNAs utilize overlapping cellular machinery for
biogenesis and function, it is not surprising that these molecules can
compete with each other for the binding factors, such as Ago2 in the
RISC complex. Competition between co-transfected siRNAs or sequen-
tially transfected siRNAs has been reported, leading to reduced activity
for the less competitive siRNAswhen co-transfected, or delayed loadinge oligonucleotides; RISC, RNA
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lished by Elsevier B.V. All rights reserof the latterly transfected siRNAs [5,6]. In addition, a recent study dem-
onstrated that transfected small RNAs, including siRNAs and miRNAs,
can globally perturb gene regulationby endogenousmiRNAsmost likely
by competition with and saturation of the endogenous RISC pathway
[7]. Several limiting factors in the RISC pathway have been proposed,
including Exportin 5 and especially Ago2 [8–11]. Reduced Ago2 level
has been demonstrated to increase competition between siRNAs [6].
In addition, we recently also found that transfected siRNAs can compete
with endogenousmiRNAs for Ago2 binding, leading to reduced levels of
Ago2-associated miRNAs or even total cellular miRNA levels, and re-
duced protein levels secondary to impaired miRNA activity that led to
increased levels of proteases targeted by miRNAs [12]. These ﬁndings
show that the pre-transfected siRNAs used to reduce the transcripts of
a target gene may reduce the activity of subsequently transfected
siRNAs, or reduce endogenousmiRNA regulation. This is particularly im-
portant when characterizing genes implicated in RISC pathway, since
secondary siRNAs targeting reporter genes or reporter genes regulated
by endogenous miRNAs are often used in such analyses. In these cases,
it is very likely that siRNA-mediated reduction of the target transcripts
can display a phenotype due to impaired RISC activity secondary to
competition.
Several proteins have been implicated in RISC pathway, including
MOV10, eIF6, C3PO complex, Exportin 5, and RHA [13–16]. RHA (DHX9)
is a helicase protein and functions in various processes. It is able to bind
single- and double-stranded RNA and single stranded DNA, and can un-
wind RNA–RNA and RNA–DNA duplexes [17]. This protein is implicated
in transcriptional regulation and was identiﬁed as a bridging factorved.
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transcriptional processing of RNAs [18–20]. In addition, RHAwas found to
associate with siRNAs and some RISC protein components including
Ago2, Dicer, and TRBP [16]. RHAwas proposed to function in RISC loading,
as evidenced by impaired siRNA activity and siRNA associationwith Ago2
in cells depleted of RHA by siRNAs [16]. However, when characterizing
the effects of siRNAs on the levels of endogenous miRNAs, we previously
found that transfection of RHA siRNA and several other siRNAs targeting
different protein-coding genes all caused reduced levels of Ago2 associat-
edmiRNAs, in amanner unrelated to loss of the target proteins [12]. These
observations prompted us to re-examine the role of RHA inRISC pathway,
since the previously observed defects caused by siRNA-mediated reduc-
tion of RHA transcripts on RISC activity might stem from siRNA/siRNA
competition.
In this study,we reduced RHAusing two different approaches, siRNA
or RNaseH-dependent antisense oligonucleotides (ASOs), and found
that the impaired RISC activity was not related to the loss of the RHA
protein, rather, it was correlated with the presence of pre-transfected
siRNAs, in a dose dependent manner. Our results indicate that RHA is
not required for siRNA loading or RISC activity, and suggest that compe-
tition effects may lead to false-positive phenotypes.
2. Materials and methods
2.1. Materials
siRNAs were purchased from Applied Biosystems or Invitrogen.
The ID numbers and sense sequences of the siRNAs used in this
study are: RHA siRNA (s4019), 5′-GAGUGUAACAUCGUAGUAAtt;
RHA-si-544, 5′-GAAGTGCAAGCGACTCTAG; NCL1 siRNA (s9312), 5′-
GGAUAGUUACUGACCGGGAtt; NPM1 siRNA (S9676), 5′-CGACAAAG
AUUAUCACUUUtt. The lower case letters represent deoxynucleotides
that are not complementary to the target mRNAs. MOV10 siRNA
(HSS106677), 5′-CCAUGUCCAUUGUAAGACCAGCUUU; PTEN siRNA
(ISIS341401), 5′-AAGUAAGGACCAGAGACAA. The following siRNAs
were purchased from IDT (RHA-si-544), 5′-GAAGUGCAAGCGACUC
UAG; Luciferase siRNA, 5′-CGUACGCGGAAUACUUCGAUU.
2′-O-methyloxylethyl modiﬁed (2′-MOE), phosphorothioate
backbone-containing RNA–DNA chimeric ASOs were synthesized
as described previously [21]. The ID numbers and sequences are: RHA
(ISIS230445), 5′-AATGGTGTTCGGAACATCTC; NCL1 (ISIS110074), 5′-
GTCATCGTCATCCTCATCAT; MOV10 (ISIS526335), 5′-GTAACAGACTG
GGTTCCGCC. The underlined nucleotides are modiﬁed with 2′-MOE.
The 10 nts in the middle are deoxynucleotides. All nucleotides are
linked with phosphorothioate backbone.
Antibodies against RHA (ab26271, 1:1000), NCL1 (ab13541, 1:1000),
MOV10 (ab80613, 1:1000), and Ago2 (ab57113, 1:1000)were purchased
from Abcam. RPL4 antibody (11302-1-AP, 1:1000) was from Proteintech.
Secondary antibodies (1:2000) conjugated with HRP for mouse
(172–1011) and rabbit (172–1019) were purchased from Bio-Rad.
2.2. Cell culture and transfection
HeLa cells were cultured in DMEM supplemented with 10% FBS,
0.1 μg/ml streptomycin, and 100 Unit/ml penicillin. Sixteen hours prior
to transfection, cells were seeded at ~50% conﬂuency in 15 cm dishes.
Transfection of siRNAs was performed using 5 μg/ml Lipofectamine
RNAiMax (Invitrogen), based on the manufacturer's procedure, at ﬁnal
concentrations as indicated in ﬁgures. Transfection of RNaseH ASOs was
performed using 4 μg/ml Lipofectamine 2000 in Opti-MEM medium
(Invitrogen) for 4 h, based on the manufacturer's instruction. Four
hours after ASO transfection,mediumwas replacedwith DMEMmedium
supplemented with 10% FCS and 1% penicillin/streptomycin. 24 h after
the ﬁrst transfection of ASOs or siRNAs, cells were washed with PBS
and re-seeded in 6-well dishes at ~50% conﬂuency. Second siRNAs were
transfected 4 h later at different concentrations using LipofectamineRNAiMax. Four hours after the second transfection, cells were washed
in plates 3 times with 1× PBS, trypsinized, and washed another 2 times
with 1× PBS to remove extracellular siRNAs. Finally, total RNA or whole
cell extract was prepared for qRT-PCR, western, or immunoprecipitation
analyses, as indicated in ﬁgure legends.
2.3. Western analysis
Equal amount of proteins (~20 μg) prepared from test cells were
separated in 4–12% SDS-PAGE and transferred to membrane. Blocking
and detection of proteins with ECL was performed as described previ-
ously [22].
2.4. RNA preparation and qRT-PCR
Total RNA was prepared from HeLa cells using the RNeasy Mini Kit
(Qiagen) for qRT-PCR to detect the levels of mRNAs. For miRNA or
siRNA analysis, total RNAwas prepared using themiRNeasy Kit (Qiagen),
based on the manufacturer's instruction. qRT-PCR using TaqMan primer
probe sets was performed as described previously [22]. The primer and
probe sequences for different mRNAs are: MOV10: forward, 5′-ATGG
TGTGGATGTGGAAGTC; reverse, 5′-AGAGTGGGAAGAGGTGAGTG; probe,
5′-TTGAACCGCAAAGAGGTGCTGAC. RHA: forward, 5′-CCACTTACTGATA
CTCCTGACAC; reverse, 5′-CAGGAACACCATAGCCAGAG; probe, 5′-TGCTT
TGAGAGCCAGATGTGGAGG PTEN: forward, 5′-AATGGCTAAGTGAAGAT
GACAATCAT; reverse, 5′-TGCACATATCATTACACCAGTTCGT; probe, 5′-
TTGCAGCAATTCACTGTAAAGCTGGAAAGG. NCL1: forward, 5′-GCTTGG
CTTCTTCTGGACTCA; reverse, 5′-TCGCGAGCTTCACCATGA; probe, 5′-CG
CCACTTGTCCGCTTCACACTCC. NPM1: forward, 5′-TCCTGCGCGGTTGTT
CTC; reverse, 5′-GGCGGCACGCACTTAGG; probe, 5′-CAGCGTTCTTTTAT
CTCCGTCCGCCT. U16 snoRNA: forward, 5′-CTTGCAATGATGTCGTAATT
TGC; reverse, 5′-TCGTCAACCTTCTGTACCAGCTT; probe, 5′-TTACTCTG
TTCTCAGCGACAGTTGCCTGC.
2.5. RNA immunoprecipitation
An equal amount (~150 μg protein) of whole cell extracts prepared
in Buffer A [25 mMTris.Cl pH 8.0; 5 mMMgCl2; 150 mMKCl; 10% glyc-
erol; 0.5 mM PMSF; 5 mM β-mercaptoethanol; one tablet of Protease
Inhibitor Cocktail/50 ml (Roche), and 100 Unit/ml RNase Inhibitor]
were incubated at 4 °C for 3 h with 30 μl Protein A beads (Roche) pre-
coated with 10 μg Ago2 antibody (ab57113). After six washes with
wash buffer (50 mM Tris.Cl, pH 7.5; 150 mM NaCl; 5 mM EDTA; 0.1%
NP-40; 20 Unit/ml of RNase Inhibitor), the co-selected RNAs were di-
rectly prepared from the beads using Tri-Reagent, dissolved in 20 μl
DEPC water, and subjected to reverse transcription-qRT-PCR analysis
for miRNAs or siRNAs. To control for loading, 10% of whole cell extract
used in immunoprecipitation was subjected to total RNA preparation
using miRNeasy kit, and the levels of U16 snoRNA were detected and
used to normalize the qRT-PCR results for miRNA and siRNA.
2.6. miRNA and siRNA detection
The levels of miRNAs and siRNAs were determined using TaqMan
qRT-PCR assay, based on themanufacturer's instructionswithminor re-
vision. Brieﬂy, 5 μl total RNA (500 ng) or Ago2 co-precipitated RNAs
were reverse transcribed in a 20 μl reaction containing 4 μl 5× RT buff-
er, 2 μl 10 mM dNTP, 1 μl RT primer speciﬁc to miRNAs or siRNA (from
Applied Systems), 1.5 μl 25 mM MgCl2, 1 μl Reverse transcriptase
(RMV), 0.5 μl RNase Inhibitor (Promega), and 5 μl DEPC water. The
reaction was performed at 16 °C for 30 min, 42 °C for 30 min, and
stopped by heating at 85 °C for 5 min. The reaction was 1:2 diluted
with DDW, and 4 μl diluted cDNAwas used in a 10 μl qRT-PCR reaction
containing 5 μl 2× master mix (Applied Biosystems) and 1 μl primer
probe mix (Applied Biosystems) speciﬁc to the miRNAs or siRNAs. The
qRT-PCR program was: 95 °C for 10 min, followed by 40 cycles of
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snoRNA, calculated, and plotted.
The primer probe sets for miRNAs were purchased from Applied
Biosystems. Assay IDs are: Let-7a (377); miR-16 (000391); miR-17
(002308); miR-21 (000397); miR-24 (000402); miR-27a (000408).
Primer probe sets for PTEN siRNA, RHA siRNA, and NCL1 siRNAwere cus-
tomized and purchased from Applied Biosystems. The primer probe sets
for RHA and NCL1 siRNAs were speciﬁc for RHA-S4019 antisense siRNA
sequence (5′-aaTTACTACGATGTTACACTC-3′) and for NCL1-S9312 anti-
sense siRNA sequence (5′-aaTCCCGGTCAGTAACTATCC-3′), respectively.
3. Results
3.1. Reduction of RHA protein does not always impair RISC activity
To ascertain if reduction of the RHA protein is the actual cause of im-
pairment of the RISC activity as observed in a previous study [16], HeLaFig. 1. RHA protein is not required for siRNA activity. A)Western analyses of RHA protein in cell
and served as a loading control. UTC, cells transfectedwithout siRNA or ASO. B) qRT-PCR analysi
(RHA-ASO) as used in panel Awere transfected for 4 hwith PTEN siRNA at different concentration
C) qRT-PCR analyses for the levels of NPM1mRNA in RHA reduced cells transfectedwith different
transfected with 5 nM RHA-si-544 or 50 nM RHA-ASO. E) qRT-PCR assay for the level of PTENmR
transfectionwith different concentrations of PTEN-siRNA, as in panel B. F) qRT-PCR for PTENmRN
sequently transfected PTEN-siRNA was determined as in panel E. The error bars represent standacells were transfectedwith a RHA speciﬁc siRNA or ASO. RHAmRNA can
thus be reduced via different pathways, siRNA-mediated RISC pathway
or ASO-mediated RNaseH pathway. 24 h after transfection, the RHA
mRNA level was reduced by more than 85% in either case, as analyzed
by qRT-PCR (data not shown). The RHA protein level was also dramati-
cally reduced, as determined by western immunoblotting (Fig. 1A), in-
dicating that similar levels of reduction of the protein were achieved
through different pathways.
Next, we analyzed if RHA protein is required for RISC activity. HeLa
cells depleted of RHA by treatment with siRNA or ASO for 24 h were
transfected again with an siRNA targeting PTENmRNA, at different con-
centrations. Total RNA was prepared 4 h after the second transfection.
The activity of PTEN siRNA was detected by measuring the levels of
PTEN mRNA using qRT-PCR (Fig. 1B). The IC50 of the PTEN-siRNA was
~0.4 nM or ~0.8 nM in control cells or in RHA-siRNA treated cells,
respectively, indicating a reduced PTEN-siRNA activity in RHA-siRNA
transfected cells. This observation is consistent with the previous study,s treatedwith 5 nMRHA siRNA (+siRNA) or 50 nMRHA ASO (+ASO). RPL4was detected
s for the levels of PTENmRNA. HeLa cells pre-treatedwith RHA siRNA (RHA-siRNA) or ASO
s, as indicated. Total RNAwas prepared and PTENmRNA levelswere detected using qRT-PCR.
concentrations of NPM1 siRNAs, as in panel B. D) qRT-PCR for the level of RHAmRNA in cells
NA in cells pre-transfected for 24 h with RHA-si-544 or RHA-ASO as in panel D, followed by
A in cells pre-treatedwith 5 nM luciferase siRNA (Leu-si) or RHA-si-544. The activity of sub-
rd deviation from three independent experiments in all panels.
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treated cells, as comparedwith control cells transfectedwith a scrambled
siRNA [16]. However, in cells depleted of RHA using ASO treatment, no
defect on PTEN siRNA activity was detected, although the RHA protein
levelwas similarly reduced by either siRNAor ASO (Fig. 1A). These results
suggest that the loss of RHA protein is not the actual cause of impaired
PTEN siRNA activity.
To determine if impaired activity could also be observed with other
siRNAs, RHA reduced cells were transfected with siRNAs targeting
Nucleophosmin (NPM1), at differentﬁnal concentrations (Fig. 1C). Con-
sistent with the results observed for PTEN siRNA, reduced NPM1 siRNA
activity was again detected only in cells pre-treated with RHA-siRNA,
but not with the RHA-ASO. The IC50 of NPM1-siRNA was comparable
in control and RHA-ASO treated cells, estimated at ~0.3 nM, indicating
that the loss of RHA protein itself did not impair the activity of the sub-
sequently transfected NPM1-siRNA. However, in RHA-siRNA treated
cells the IC50 of NPM1-siRNA was increased to ~0.6 nM, indicating
that the impaired RISC activity is not unique to a speciﬁc siRNA. Togeth-
er, these results demonstrate that the impaired RISC activity is not due
to loss of the RHA protein, and suggest that it is very likely a conse-
quence of competition between the pre-existing RHA-siRNA and the
subsequently transfected siRNAs, as reported previously [6].
In the previous study [16], RHA was reduced using siRNAs with se-
quences different from those employed here, however, the impaired
RISC activity is not due to unknown effects related to RHA-siRNA
sequence. This view was supported by the fact that although the same
siRNA as used in the previous study (RHA-si-544, corresponding to
the siRNA targeting the RHA mRNA position at 544–564) caused a
signiﬁcant reduction of RHA mRNA, as was the case of RHA-ASO
(Fig. 1D), reduced PTEN siRNA activity was only observed in the
RHA-si-544 treated cells, but not in RHA-ASO treated cells (Fig. 1E),
again indicating that the reduced siRNA activity does not stem from de-
pletion of RHA protein, rather, it is due to the presence of RHA-siRNAs,
in a sequence independent manner.
Interestingly, we note that in the previous study, reduced RISC activ-
ity was observed with RHA-siRNAs when compared with a control
siRNA [16]. A similar effect was also detected in the current study
using a luciferase siRNA as a control. The results showed that whereas
the RHA-si-544 siRNA led to a signiﬁcant reduction in PTEN-siRNA ac-
tivity, the luciferase control siRNA only caused slight defects (Fig. 1F),
consistent with the previous report [16]. These observations suggest
that a functionally inactive siRNA may be less competitive for endoge-
nous RISC components than active siRNAs. This view is supported by
our previous observations that an inactive siRNA targeting a snoRNA
(U16) caused less reduction of endogenous miRNAs when compared
with other active siRNAs targeting endogenous mRNAs [12], and that
different siRNAs exhibited different abilities to compete [5,6].
3.2. Transfection of a siRNA targeting Nucleolin can also cause similar
reduction of RISC activity
Next, we reasoned that if the impaired activity of PTEN- or NPM1-
siRNA resulted from competition with RHA-siRNAs for RISC compo-
nents, siRNAs targeting other genes should also cause similar effects.
To conﬁrm this hypothesis, HeLa cells were ﬁrst transfected with
siRNA or ASO targeting Nucleolin (NCL1), a protein involved in ribo-
some biogenesis [23]. 24 h later, PTEN- or NPM1-siRNAwas transfected
and the levels of the target mRNAs were determined by qRT-PCR. As
expected, the NCL1 protein, but not RHA protein, was dramatically
reduced by treatment with either NCL1-siRNA or NCL1-ASO (Fig. 2A).
Once again, cells pre-treated with NCL1-siRNA, but not with NCL1-ASO,
exhibited reduced activity of the PTEN-siRNA (Fig. 2B) or NPM1-siRNA
(Fig. 2C), indicating that the impaired siRNA activity stems from the pres-
ence of pre-transfected siRNAs and is not due to the reduction of the
NCL1 protein. Interestingly, reduction in siRNA activity appears greater
in NCL1-siRNA treated cells than in RHA-siRNA treated cells, althoughin both cases the same concentration of pre-transfected siRNAs was
used (5 nM), suggesting that different siRNAs are differentially favored
by the RISC components, consistent with previous reports [6,12]. Togeth-
er, these results suggest that other pre-existing siRNAs can also affect
siRNA activity in a way independent of target reduction, most likely due
to competition between siRNAs.
3.3. Depletion of RHA protein does not affect siRNA loading
It has been reported that the RHA protein is required for RISC load-
ing, based on the observations that the amount of siRNAs that co-
immunoprecipitated with Ago2 was lower in RHA-siRNA treated cells
than that in control cells [16]. However, the reduced siRNA loading
may also stem from competition between siRNAs for limited RISC
factors such as Ago2. To discriminate these possibilities, HeLa cells
were transfected with siRNA or ASO targeting RHA, or targeting NCL1
as a control, followed by transfection of 5 nM PTEN-siRNA. As expected,
themRNA levels of RHAorNCL1were reduced bymore than 80% in cells
treated with corresponding siRNAs or ASOs (Fig. 3A). Consistently, the
PTEN siRNA activity was again reduced by pre-transfection of either
RHA- or NCL1-siRNA, and not by ASOs (Fig. 3B). The total cellular levels
of the transfected PTEN siRNAwere comparable in different test cells, as
detected using qRT-PCR analysis for the antisense strand siRNA (Fig. 3C),
suggesting that the transfection efﬁciency was not signiﬁcantly affected
by the ﬁrst transfection, in agreement with the previous observations
[16].
Next, immunoprecipitation was performed using an Ago2 antibody,
and co-precipitated PTEN antisense siRNA was analyzed using TaqMan
qRT-PCR assay. Similar to the previous report [16], the level of Ago2-
associated PTEN siRNA was much lower in RHA-siRNA treated cells, as
compared with control cells (Fig. 3D), indicating that loading of PTEN
siRNA to RISC was impaired in RHA-siRNA treated cells. However, the
reduced siRNA loading was not due to the loss of the RHA protein,
since ASO-mediated reduction of RHA had no signiﬁcant effect on
PTEN siRNA loading (Fig. 3D). Importantly, impaired siRNA loading
was also observed in cells pre-treated with NCL1-siRNA, but not with
NCL1-ASO, suggesting that the loading defect probably resulted from
competition between siRNAs for binding to RISC component, especially
Ago2. Note that the reduced siRNA loading was not due to decrease in
the level of Ago2 protein, as no signiﬁcant reduction or even a slightly
increased level of Ago2 protein was observed in siRNA pre-treated
cells (Fig. 3E). Together, our results indicate that impaired PTEN siRNA
loading is not due to reduction of RHA (or NCL1) protein, and suggest
that the pre-transfected siRNAs lead to detrimental effects on siRNA
loading and RISC activity.
3.4. siRNA loading is impaired by the presence of pre-transfected siRNAs in
a dose dependent manner
Competition between different siRNAs has been reported previously
[5,6,24]. If this is the actual cause of the observed defects in PTEN-siRNA
loading and activity, stronger defects should be observed in cells pre-
transfected with higher levels of siRNAs. To test this hypothesis, HeLa
cells were transfected with 0.5 or 5.0 nM RHA-siRNA for 24 h, followed
by transfectionwith 5 nMPTEN-siRNA for 4 h. The RHA protein was re-
duced to similar levels by RHA-siRNA treatment at either concentration,
as determined by western analysis (Fig. 4A). The transfection efﬁciency
of PTEN-siRNA was also comparable between control and siRNA pre-
treated cells, as similar levels of total cellular PTEN-siRNA were ob-
served (Fig. 4B).
Next, the levels of Ago2-associated PTEN siRNAwere determined by
immunoprecipitation followed by qRT-PCR assay. Again, reduced siRNA
loading was observed in RHA-siRNA transfected cells (Fig. 4C). Impor-
tantly, the loading defect was greater in cells transfected with higher
levels of RHA-siRNA, as ~50% or 6% PTEN-siRNA was co-precipitated
from cells pre-transfected with 0.5 or 5 nM RHA-siRNAs, respectively,
Fig. 2. Pre-treatment with NCL1-siRNA, but not ASO, also reduced RISC activity. A)Western analysis for NCL1 protein levels in cells transfected with 5 nMNCL1 siRNA or 50 nMASO, as in
Fig. 1A. RPL4was detected and servedas a loading control. B) qRT-PCRanalysis for the levels of PTENmRNA in control or different NCL1 reduced cells thatwere transfected againwith PTEN
siRNA, as in panel B. C) qRT-PCR for the levels of NPM1mRNA in control or NCL1 reduced cells that were transfectedwith NPM1 siRNA at different concentrations. The error bars represent
standard deviation from three parallel experiments in all panels.
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were co-immunoprecipitated with Ago2 from cells transfected with
5 nM RHA-siRNA as compared with that from cells transfected with
0.5 nM siRNA. These results suggest that RHA-siRNAs compete with
PTEN-siRNA for Ago2 binding, in a dose dependent manner.
A similar effect was also observed in cells pre-transfected with
NCL1-siRNA. The NCL1 protein was reduced to similar levels with 0.5
and 5 nM NCL1-siRNAs (Fig. 4D), and the total cellular levels of subse-
quently transfected PTEN-siRNA were also comparable in these test cells
(Fig. 4E). Again, a stronger defect in PTEN-siRNA loading was observed
in cells transfectedwithhigher concentrationofNCL1-siRNA(Fig. 4F). Op-
posite to PTEN-siRNA, more NCL1-siRNAs were co-immunoprecipitated
from cells transfected with 5 nMNCL1-siRNA than from cells transfected
with 0.5 nM siRNA, consistentwith the results obtainedwith RHA-siRNA.
Together, these data indicate that pre-transfected siRNAs can reduce the
loading of newly transfected siRNAs due to competition, and support
the view that the siRNA loading defects observed in the previous study
were not due to reduction of the RHA protein.3.5. Transfected siRNAs, but not depletion of the RHA protein, can also
reduce endogenous miRNA levels
We recently demonstrated that the levels of endogenous miRNAs
could be reduced by transfection of different siRNAs including the
RHA-siRNA [12]. To determine if the RHA protein itself is involved in
the accumulation of endogenous miRNAs, the protein was reduced by
either RHA-siRNA or -ASO, and the levels of six miRNAs were analyzed
using qRT-PCR assay (Fig. 5A). A signiﬁcant reduction was detected for
all the six tested miRNAs in RHA-siRNA treated cells, consistent with
our recent observation. However, no signiﬁcant level change was
observed in RHA-ASO treated cells, indicating that the RHA protein is
not required for the accumulation of these miRNAs. Consistently, the
levels of Ago2-associated miRNAs were also dramatically reduced only
in cells treatedwith RHA-siRNA, but not with RHA-ASO, as demonstrat-
ed by RNA-immunoprecipitation and qRT-PCR assay (Fig. 5B). To fur-
ther conﬁrm the view that miRNA reduction is due to siRNA/miRNAcompetition, HeLa cells were transfected with two different concentra-
tions of RHA- or NCL-siRNAs, and the levels of miR-16 andmiR-21were
analyzed. Indeed, a greater reduction ofmiRNAswas found in cells treated
with higher concentrations of either siRNA (Fig. 5C., left and right panels,
respectively). In addition, the functionally inactive luciferase siRNA only
exhibited much less effect on the levels of miRNAs as compared with
the RHA-siRNA (Fig. 5D), consistent with their effects on the activity of
subsequently transfected siRNAs (Fig. 1F), further supporting the view
that functionally inactive siRNAs can be less competitive than active
siRNAs. Together, these results indicate that the presence of RHA
(or NCL1) siRNA, but not reduction of the proteins, signiﬁcantly af-
fects the accumulation of endogenous miRNAs, due to competition
with RISC components.3.6. Unlike RHA, MOV10 protein appears to be involved in siRNA-RISC
activity
To evaluate the suitability of ASO-mediated mRNA reduction in
characterizing protein effects on RISC pathway and to rule out the pos-
sibility that the phenotypes of RHA reduction were unexpectedly
masked by ASO treatment, we reduced MOV10 protein using either a
speciﬁc siRNA or anASO. It has been shown that siRNA-mediated reduc-
tion of MOV10 protein in human cells reduced RISC activity, as deter-
mined using a reporter gene containing EGFP whose expression was
under the regulation of miR-21 [13]. The involvement of MOV10 in the
RISC pathway was also demonstrated by analyzing a mutant Armitage
(Arm), the Drosophila homologue of MOV10, which failed to silence
Stellate, a gene regulated endogenously by siRNA, and failed to cleave
siRNA target in an in vitro assay [25], ruling out the possibility of siRNA-
competition derived effects.
The MOV10-siRNA was transfected at 0.75 or 6 nM ﬁnal concen-
trations. As a control, a MOV10-ASO was also transfected to reduce
the protein expression. 24 h after initial transfection, PTEN-siRNA
was transfected at different concentrations for an additional 4 h. As
expected, the MOV10 protein level was dramatically reduced by
treatment with the siRNA at two different concentrations or with
Fig. 3. Depletion of RHA does not affect siRNA loading. A) Reduction of RHA or NCL1 mRNAs by transfection of either 5 nM siRNAs or 50 nM ASOs speciﬁc to the genes, as determined by
qRT-PCR analyses. UTC, cells transfected without siRNA or ASO. B) qRT-PCR results for the reduction of PTENmRNA by transfection of 5 nM PTEN siRNA in different test cells. C) The total
cellular levels of transfected PTEN siRNA appear to be comparable in different test cells as used in panel B, as determined using qRT-PCR. D) qRT-PCR for the levels of Ago2 co-precipitated
PTEN siRNAs. Immunoprecipitation was performed using an Ago2 antibody from an equal amount of extracts prepared from different test cells, as used in Panel B. UTC, control cells
transfected with PTEN siRNA. E) Western analysis for Ago2 protein in different test cells transfected with siRNA or ASOs. The asterisk indicates a non-speciﬁc product detected by the
Ago2 antibody. UTC, control cells transfected without siRNA or ASO. The error bars represent standard deviation from three parallel experiments in all panels.
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treated with 0.75 nM MOV10 siRNA, as compared with that in con-
trol cells (Fig. 6B). Importantly, reduced PTEN siRNA activity was
also observed in cells depleted of MOV10 by ASO treatment, indicating
that reduction in the siRNA activity was not solely a siRNA competition
effect and thatMOV10protein is indeed involved inRISC activity. Interest-
ingly, a greater reduction of PTEN-siRNA activity was found in cells treat-
ed with 6 nM MOV10 siRNA than in cells treated with 0.75 nM siRNA,
indicating that the reduced PTEN-siRNA activity partially attributes to
the competition between theMOV10 siRNA and the PTEN-siRNA. Despite
of this complexity, our results indicate that the approachof ASO-mediated
protein reductionmay be effectively employed to characterize the roles of
proteins in RISC activity, and further support the view that RHA protein is
not required for RISC activity or siRNA loading.The potential effect of MOV10 reduction on siRNA loading was deter-
mined by analyzing the levels of Ago2 co-precipitated PTEN-siRNAs
from cells pre-treated with siRNAs or ASOs. The total cellular levels of
transfected PTEN-siRNA were comparable in all test cells; however, the
level of Ago2-associated PTEN siRNA was much lower in MOV10-siRNA
treated cells, as comparedwith that in control cells (Fig. 6C). Interestingly,
the impaired PTEN-siRNA loading appears not to be an effect related to re-
duction of MOV10 protein, since no siRNA loading defect was found in
MOV10-ASO treated cells, although theMOV10 protein was also dramat-
ically reduced in this case. These results suggest thatMOV10protein is not
required for association of siRNA with Ago2.
Since a stronger reduction of PTEN-siRNA activity was found in cells
treatedwith higherMOV10-siRNA concentration (Fig. 6B), we next asked
whether the impairment of RISC activity depends on the concentration of
Fig. 4. siRNA loading can be affected by the pre-transfected siRNAs in a dose dependent manner. A)Western analysis for RHA protein in cells transfected with different concentrations of
siRNAs. RPL4was detected and served as a loading control. B) qRT-PCR for the cellular levels of transfected PTEN siRNA in cells pre-transfectedwith 0.5 or 5.0 nMRHA siRNAs. C) Less PTEN
siRNA was associated with Ago2 in cells pre-transfected with higher concentration of RHA siRNA. Immunoprecipitation with Ago2 antibody and qRT-PCR for PTEN and RHA siRNAs were
performed as in Fig. 3D. The relative levels of RHA siRNAwere calculated based on the level of RHA siRNA co-precipitatedwith Ago2 from cells transfectedwith 5 nMRHA siRNA. D)Western
analysis for NCL1 protein in cells treatedwith NCL1 siRNAs. RPL4 served as a loading control. E) Total cellular levels of transfected PTEN siRNA in different test cells, as in panel B. F) The relative
levels of Ago2-associated PTEN and NCL1 siRNAs in different test cells, as in panel C. The relative levels of NCL1 siRNA were calculated based on the level of NCL1 siRNA co-precipitated with
Ago2 from cells transfected with 5 nM NCL1 siRNA. The error bars represent standard deviation from three parallel experiments in all panels.
Fig. 5. The levels of cellular and Ago2-associatedmiRNAs can be reduced in cells transfectedwith siRNAs but not ASOs. A) ThemiRNA levels in control cells and cells depleted of RHA using
5 nM siRNAs or 50 nM ASOs. 24 h after transfection, total RNA was prepared and the levels of the miRNAs were determined using qRT-PCR, normalized to the level of U16 snoRNA, and
plotted. B) The levels of Ago2-associatedmiRNAs reduced in cells transfectedwith siRNAs but not ASOs. RNA immunoprecipitatedwith Ago2 fromextracts prepared from different cells as
used in panel A were analyzed using qRT-PCR for the levels of miRNAs. C) GreatermiRNA reduction can be observed in cells transfectedwith higher siRNA concentrations. Total RNA pre-
pared from cells transfectedwith 0.5 or 5.0 nMof siRNAs targeting RHAorNCL1was analyzed for the levels ofmiR-16 (left panel) andmiR-21 (right panel). D) qRT-PCR formiRNA levels in
cells transfected with 5 nM Luciferase siRNA (Luci-si) or RHA-siRNA for 24 h, as in panel A. The error bars represent standard deviation from three parallel experiments in all panels.
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Fig. 6. ASO-mediated reduction of MOV10 impaired siRNA activity. A) Western analysis for the levels of MOV10 protein in cells transfected with 0.75 or 6.0 nMMOV10 siRNA or 50 nM
ASO. RPL4 was detected and served as a loading control. B) qRT-PCR for the levels of PTEN mRNA in control cells or different MOV10-depleted cells that were subsequently transfected
again with PTEN siRNA at different concentrations. C) PTEN siRNA association with Ago2 was not affected by MOV10 reduction. The levels of transfected cellular or Ago2-co-precipitated
PTEN siRNA were determined using qRT-PCR. D) RT-PCR for the levels of MOV10 mRNA in cells treated for 24 h with different concentrations of MOV10-ASOs. E) Western analysis for
MOV10 protein. GAPDH was detected and served as a loading control. F) qRT-PCR for the levels of PTEN mRNA in different ASO treated cells that were transfected again with different
concentrations of PTEN siRNA for 4 h, as described in Materials and methods. The error bars represent standard deviation from three parallel experiments in all panels.
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likely, that the transfected oligonucleotides interact with other nucleic
acid binding protein(s), which might be involved in RISC pathway. To
examine this possibility, HeLa cells were transfected with different con-
centrations of MOV10-ASO, which is composed of hypermodiﬁed ol-
igonucleotides that bind more proteins than canonical RNAs [26].
As expected, moderate mRNA and protein reduction was observed
with 10 nM ASOs, whereas a similar and dramatic reduction (more
than 90%) at both mRNA and protein levels was obtained in cells
treated with 30 or 60 nM ASO concentrations (Fig. 6A and B). Consis-
tent with the role of MOV10 in RISC activity, ~50% reduction at the
protein level caused detectable impairment of RISC activity (Fig. 6F).
However, a stronger defect in siRNA activity was found in cells treated
with higher ASO concentrations. Importantly, no greater impairment
was observed in cells treated with 60 nM ASO than in cells transfected
with 30 nM ASO, in both cases theMOV10 protein was reduced to sim-
ilar levels. These results, together with the observations from Fig. 1 and
2, suggest that the impaired RISC activity in MOV10-ASO treated cells is
not due to unexpected effects of ASOs, rather, it is due to reduction of
MOV10 protein.4. Discussion
Competition between RISC-associated small RNAs has been demon-
strated in different organisms, including mammals [7,24]. We recently
found that transfection of different siRNAs in mammalian cells can
alter the levels ofmany endogenousmiRNAs, largely due to competition
for Ago2 [12]. Previous work from our group also showed that different
siRNAs can compete with each other, leading to a reduced activity or
loading of less competitive siRNAs or subsequently transfected siRNAs
[5,6]. Competition can thus lead to false-positive results especially
when characterizing proteins implicated in RISC pathway. Unlike previ-
ous reports [16], in this study, we found that the RHA protein is not
required for RISC activity or siRNA loading.
RHA was shown to be associated with RISC components by co-
isolation using biotinylated siRNAs and by co-immunoprecipitation
with different RISC pathway proteins, including Ago2, Dicer, and TRBP
[16]. These ﬁndings led to a presumption that RHA might play a role
in RISC pathway. The hypothesis was examined by reducing RHA
using siRNAs targeting the RHA mRNA, followed by transfection of
other siRNAs targeting reporter genes (GFP or CDK9) and determining
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formation of active RISC for GFP siRNAswere found in RHA-siRNA treat-
ed cells, as compared with control cells, leading to the conclusion that
RHAprotein functions in RISC loading [16]. Consistentwith the previous
observations, defects in siRNA activity and loading were also found in
the current study in cells treated with different RHA-siRNAs. How-
ever, the observed defects, although reproducible, are not due to
reduction of the RHA protein, since dramatic reduction of RHA by
an ASO-directed RNaseH cleavage approach had no effect on siRNA activ-
ity nor loading into RISC. These ﬁndings indicate that the RHA protein
itself is not required for RISC activity or siRNA loading, rather, the ob-
served defects were derived from competition between pre-transfected
RHA-siRNA and subsequently transfected siRNAs. This view is further
supported by our observations that transfection of NCL1-siRNA also
caused similar defects in siRNA activity and loading, however, transfec-
tion of NCL1-ASO had no such effect, although the NCL1 protein level
was dramatically reduced in either case. In addition, we have found
reduced RISC activities in cells pre-transfected with siRNAs, but not
ASOs, targeting several different helicase proteins, including DDX30
and DDX36 (our unpublished data and [12]). These results further con-
ﬁrm that pre-transfected siRNAs, but not reduction of the targeted RHA
or NCL1 protein, impaired the activity and loading of subsequently
transfected siRNAs.
It has been shown in our previous study that eight different siRNAs,
including an inactive siRNA that targets a snoRNA, all caused reduced
levels of miRNAs upon transfection in an Ago2 dependent manner
[12], suggesting that siRNAs that bind Ago2 might be able to affect sub-
sequent siRNA loading or activity due to limited level of Ago2. This view
is further supported by our current ﬁnding that a luciferase siRNA,
which has no physiological target, also slightly reduced siRNA activity
(Fig. 1F). In addition, a previous study has shown that GFP siRNA, a com-
monly used negative control siRNA, could reduce non-target mRNAs in
a dose dependent manner, and the modulated mRNAs have target se-
quences homologues to the siRNA as small as eight base-pairs in size
[27], suggesting that the GFP siRNA may also be incorporated into
RISC complex and thus may be able to compete.
The detrimental effects of pre-existing siRNAs on the loading of sub-
sequently transfected siRNAs are most likely due to competition for
RISC components, as evidenced by the observations that higher siRNA
concentrations caused stronger defects in the siRNA loading, and that
transfection of either RHA- or NCL1-siRNAs, but not ASOs, reduced the
levels of endogenous miRNAs. It has been shown that reducing the
level of Ago2 increased competition of siRNAs [6], and that Ago2 is a
limiting factor in the RISC pathway [10]. The limited Ago2 protein
could be occupied bypre-transfected siRNAs, in a siRNAdose dependent
manner, leading to reduced levels of available Ago2 for subsequently
transfected siRNAs. This is supported by our ﬁndings that pre-
transfection of higher level of RHA- or NCL1-siRNAs reduced the
levels of Ago2-associated, subsequently transfected PTEN siRNAs, where-
as the Ago2-associated RHA- or NCL1-siRNAs concomitantly increased
(Fig. 4). Interestingly, it appears that different siRNAs may have different
afﬁnities to the RISC components, since stronger defects in siRNA activity
and loading were observed for NCL1 siRNA, as compared with RHA
siRNA. This is consistent with the previous observations that different
siRNAs had different abilities to compete [5,6], suggesting a sequence de-
pendent competition. It is possible that functionally inactive siRNAs may
have less capacity in competition, as evidenced by our ﬁndings that lucif-
erase siRNA, which has no endogenous target, only slightly reduced
siRNA activity (Fig. 1F); and thatU16 siRNA,which is inactive in target re-
duction, reduces miRNA levels to a lesser extent than other siRNAs that
actively target endogenous mRNAs [12].
In a previous study, it was shown that competition between sequen-
tially transfected siRNAs mainly occurred within 12 h after the ﬁrst
transfection [6], whereas in the current studywe showed that competi-
tion still existed 24 h after initial transfection. The difference in the
duration of the competitive effect is most likely due to a difference inexperimental design. In the previous study the activity of the second
siRNA was measured 24 h after second transfection [6], whereas in
the current study it was measured 4 h after second transfection. Thus
the total time during which strong competition occurred was 36 h
post initial transfection in the previous study and was more than 28 h
in the current study. In principal, competition could occur when the
endogenous RISC component is saturated. Thus, the time slot for Ago2
to be released could vary with different siRNA concentrations and
sequences, or even with different cell types. In addition, it may also
stem from the differences in cellular concentrations of the ﬁrst siRNA,
or from sequence-dependent effects. This sequence- and activity-
dependent competition of siRNAs may explain the previous observa-
tion that RHA-siRNA treated cells exhibited reduced RISC activity
and loading relative to cells transfected with a control siRNA duplex
[16], which may not be effectively or stably loaded into RISC prior to
transfection of the subsequent siRNAs.
In contrast to RHA, we were able to conﬁrm that MOV10 protein is
required for RISC activity, since reduction of MOV10 by either siRNA
or RNaseH ASO all impaired siRNA activity, suggesting that the ap-
proaches we used to characterize RHA are suitable to distinguish RISC
defects. The impaired RISC activity in MOV10 reduced cells is consistent
with the previous observation in Drosophila where the mutant MOV10
homologue, Arm, impaired RISC activity [25], ruling out the possibility
of siRNA competition effects. However, stronger defects in RISC activity
were observed in cells treated with higher level of MOV10-siRNA,
suggesting that siRNA competition effects also partially contribute to
the observed phenotypes. Interestingly, siRNA association with Ago2
was not affected by ASO-mediated MOV10 reduction, suggesting that
MOV10 effects at a later stage during RISC function. This is in agreement
with a previous study showing thatMOV10most likely plays a role after
unwinding of duplex siRNA into single stranded siRNA [25].
Competition between siRNAs can impair the activity and loading of
subsequently transfected siRNAs, raising a further concern about the
speciﬁcity of the observed phenotypes in siRNA-activities when reduc-
ing a target protein. This is especially important when characterizing
proteins implicated in the RISC pathway, since both the subsequently
transfected siRNAs and endogenous miRNAs can be affected by the
pre-transfected siRNAs. A negative siRNA is apparently not sufﬁcient
for control of speciﬁcity, since inactive siRNAs may not exhibit equal
competition capacity. In this regard, a siRNA targeting an irrelevant
gene might be a better control. On the other hand, conclusive interpreta-
tion should be supported by inactivating or depleting the target protein
using other alternative approaches, such as ASO-mediated RNaseH cleav-
age method or genetic mutational analyses.
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